WO2010147194A1 - 精子用希釈液、及び、これを用いた人工授精方法 - Google Patents
精子用希釈液、及び、これを用いた人工授精方法 Download PDFInfo
- Publication number
- WO2010147194A1 WO2010147194A1 PCT/JP2010/060320 JP2010060320W WO2010147194A1 WO 2010147194 A1 WO2010147194 A1 WO 2010147194A1 JP 2010060320 W JP2010060320 W JP 2010060320W WO 2010147194 A1 WO2010147194 A1 WO 2010147194A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sperm
- frozen
- egta
- artificial insemination
- edta
- Prior art date
Links
- 230000009027 insemination Effects 0.000 title claims abstract description 54
- 239000003085 diluting agent Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 18
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims abstract description 57
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 51
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 30
- 239000002738 chelating agent Substances 0.000 claims abstract description 17
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 16
- 210000004291 uterus Anatomy 0.000 claims abstract description 16
- 102000004127 Cytokines Human genes 0.000 claims abstract description 13
- 108090000695 Cytokines Proteins 0.000 claims abstract description 13
- 239000003270 steroid hormone Substances 0.000 claims abstract description 11
- 230000005012 migration Effects 0.000 claims abstract description 8
- 238000013508 migration Methods 0.000 claims abstract description 8
- 238000007865 diluting Methods 0.000 claims abstract description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims description 107
- 239000000243 solution Substances 0.000 claims description 48
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 44
- 238000010790 dilution Methods 0.000 claims description 35
- 239000012895 dilution Substances 0.000 claims description 35
- 229960000890 hydrocortisone Drugs 0.000 claims description 22
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 210000003754 fetus Anatomy 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 11
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims description 8
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 claims description 8
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 7
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 7
- 150000001885 cortisol derivatives Chemical class 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 238000002513 implantation Methods 0.000 abstract description 21
- 230000035935 pregnancy Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 63
- 230000026731 phosphorylation Effects 0.000 description 23
- 238000006366 phosphorylation reaction Methods 0.000 description 23
- 241000282887 Suidae Species 0.000 description 21
- 241000282898 Sus scrofa Species 0.000 description 20
- 230000019100 sperm motility Effects 0.000 description 20
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000011575 calcium Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 230000004720 fertilization Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000009395 breeding Methods 0.000 description 8
- 230000001488 breeding effect Effects 0.000 description 8
- 244000144972 livestock Species 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000012173 estrus Effects 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 230000009822 protein phosphorylation Effects 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 239000007798 antifreeze agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001158 estrous effect Effects 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000469 sperm hypomotility Toxicity 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Definitions
- the present invention relates to a dilution solution for sperm used for diluting frozen sperm for artificial insemination such as non-human mammals, particularly pigs, and an artificial insemination method using the same.
- Non-Patent Document 1 and Non-Patent Document 2 it is equivalent to nothing in the pig farming industry.
- the present inventors have proposed an artificial insemination method using frozen sperm obtained by removing seminal plasma from collected sperm (Japanese Patent Application No. 2007-325313).
- the fertilization rate is improved by artificially inseminating frozen sperm in a diluted solution containing seminal plasma.
- the seminal plasma added to the diluent tends to be unstable in conception rate and implantation rate because its components vary from individual to individual and from season to season.
- the present invention has been made in view of the above-described matters, and the object thereof is to obtain a conception rate equal to or higher than that of a dilute solution containing seminal plasma, even if it is a dilute solution containing seminal plasma. It is providing the dilution liquid for sperms, and the artificial insemination method using the same.
- the dilution for sperm according to the first aspect of the present invention is It contains a chelating agent that forms a complex with calcium ions.
- the chelating agent is EGTA.
- the chelating agent is preferably EGTA or EDTA.
- an immunosuppressive factor that suppresses leukocyte migration.
- the immunosuppressive factor is preferably one or more selected from steroid hormones and cytokines.
- the steroid hormone is at least one selected from cortisol and cortisol derivatives.
- the cortisol derivative is preferably at least one selected from dexamethasone, prednisone, and hydrocortisone.
- cytokine is preferably one or more selected from macrophage migration inhibitory factor and Serpin E1.
- the frozen sperm is preferably a non-human mammal frozen sperm.
- the non-human mammal is a multiple animal.
- the multiple animal is a pig.
- the artificial insemination method comprises: Frozen spermatozoa frozen by removing seminal plasma from semen collected from non-human mammals, and preparing artificial semen by diluting with the above sperm diluent, The artificial semen is injected into the uterus of the non-human mammal to perform artificial insemination.
- a pig as the multiple animal.
- the sperm dilution according to the present invention does not contain any seminal plasma, there is no problem of bacterial infection and it can be used for production of specific disease-free SPF pigs.
- FIG. 1 It is a figure which shows the measurement result of the sperm motility in Experimental example 2.
- FIG. It is a figure which shows the detection result of the cytokine in the seminal plasma in Experimental example 3. It is a figure which shows the relative value of the intrauterine white blood cell count in Example 2.
- the sperm diluent according to the present embodiment contains a chelating agent that forms a complex with calcium ions in the basic diluent described later.
- a chelating agent that forms a complex with calcium ions in the basic diluent described later.
- mitochondria are present in the middle part of the sperm, where energy (ATP) used for sperm movement is produced.
- energy used for sperm movement
- calcium ions act on mitochondria (more specifically, an enzyme that produces ATP)
- ATP production is activated, so sperm moves violently, but when sperm is activated quickly, Sperm will die before reaching the fallopian tube.
- a chelating agent is contained in the diluted solution, and this chelating agent forms a complex with calcium ions, thereby suppressing the calcium ions from acting on mitochondrial mitochondria. is doing.
- the sperm diluent according to the present embodiment can be obtained by adding a chelating agent that forms a complex with calcium ions to the basic diluent.
- the basic dilution liquid is a dilution liquid prepared so that the collected semen can be kept at room temperature for a certain period of time without deteriorating the function of the sperm in the semen, and glucose and citric acid. It is a liquid containing components such as sodium, sodium bicarbonate, EDTA-2Na, citric acid, tris, and potassium chloride.
- Modena liquid (0.15M glucose, 26.7 mM sodium citrate, 11.9 mM sodium hydrogencarbonate, 15.1 mM citric acid, 6.3 mM EDTA-2Na, 46.6 mM Tris and 1,000 IU / ml penicillin).
- the chelating agent is not particularly limited as long as it is a substance that specifically forms a complex with calcium ions.
- Ethylene glycol tetraacetic acid ethyleneglycol Bis (2-aminoethyl) -N, N, N ′, N′— (tetraacetic acid)
- EGTA ethyleneglycol Bis (2-aminoethyl) -N, N, N ′, N′— (tetraacetic acid)
- EGTA ethyleneglycol Bis (2-aminoethyl) -N, N, N ′, N′— (tetraacetic acid)
- EDTA ethylenediaminetetraacetic acid
- EGTA ethylenediamineacetic acid
- EDTA is a substance that forms complexes with various divalent ions such as magnesium ions and zinc ions in addition to calcium ions.
- both EDTA and EGTA are added, calcium ions that could not be chelated with EDTA can be chelated with EGTA, and most calcium ions present in the basic diluent can be chelated.
- the concentration of EDTA added to the base diluent must be increased.
- the basic diluent contains various divalent ions such as magnesium ions and zinc ions other than calcium ions. If the EDTA concentration is too high, these divalent ions may be excessively chelated. Yes, it can affect sperm function (fertilization). For this reason, it is preferable to add both EDTA and EGTA.
- the EDTA concentration in the sperm diluent is preferably about 3 to 9 mM / L and the EGTA concentration is about 3 to 9 mM / L from the experimental results described below.
- the EDTA concentration is 6.3 mM and the EGTA concentration is 6 mM.
- the sperm dilution solution contains an immunosuppressive factor so that sperm, embryos and the like are not phagocytosed by leukocytes in the uterus. Because sperm is a foreign body for females, when sperm enters the uterus, leukocytes such as neutrophils and macrophages migrate, and sperm and embryos are phagocytosed, affecting the implantation rate.
- Implantation rate is the ratio of fetus in utero to the number of eggs.
- multiple ovarian animals such as pigs ovulate 10 to 20 eggs, it is required to fertilize more eggs once and give birth to a large number of fetuses for production efficiency.
- the above-described phagocytosis is unlikely to occur, so the seminal plasma in semen contains an immunosuppressive factor that suppresses leukocyte migration. This is thought to prevent attacks on the embryo.
- the immunosuppressive factor capable of suppressing leukocyte migration is contained in the sperm dilution solution, phagocytosis of sperm and embryos can be suppressed, and an improvement in the implantation rate can be realized.
- steroid hormones and cytokines are preferable.
- cortisol which is a component contained in seminal plasma is preferable.
- the cellular immune mechanism is prevented from functioning and migration of leukocytes and the like is blocked.
- phagocytosis of sperm and embryo is suppressed, and an improvement in the implantation rate is realized.
- the amount of cortisol added to the sperm diluent used in one artificial insemination is preferably about 100 ng to 10,000 ng. More preferably, it is 500 ng to 5,000 ng. This is approximately the same as the amount of cortisol contained in all seminal plasma ejected from boars in natural mating.
- Cortisol is originally contained in seminal plasma, decomposed into the uterus within 1-2 days after injection, and discharged outside the body, and because it is injected locally, it does not spread throughout the body. There is no risk of adverse effects such as the birth of malformed piglets without adversely affecting the living body.
- dexamethasone dexamethasone, prednisolone, hydrocortisone and the like, which are cortisol derivatives, are considered to be chemically changed to cortisol and have similar immunosuppressive effects. These may be used.
- Macrophage migration factor and Serpin E1 are both substances contained in seminal plasma.
- Macrophage migration inhibitory factor and cytokines such as Serpin E1 are signal transduction substances, and suppress the unnecessary accumulation of leukocytes such as neutrophils and macrophages in the uterus and exert an immunosuppressive action.
- the frozen sperm may be added to the sperm diluent when the frozen sperm is thawed.
- the thawing of frozen sperm is performed at 37 ° C. for 60 seconds when using a sperm filled in a 5 ml straw, and at 0.5 ° straw for 35 seconds at 35 ° C., preferably at 37 ° C.
- the treatment may be performed for 20 seconds, more preferably at 70 ° C. for 8 seconds, and most preferably in warm water at 60 ° C. for 8 seconds.
- the sperm dilution may be added directly to the frozen sperm.
- the amount of artificial semen used for one artificial insemination of pig is about 50 ml, and the final concentration of sperm in the artificial semen is 1 ⁇ 10 6 cells / ml to 1 ⁇ 10 9 cells / ml, preferably 1 ⁇ 10 6. What is necessary is just to prepare so that it may become an order of 8 cells / ml.
- artificial insemination can be performed by injecting the prepared artificial semen into the womb of a sow that has reached estrus.
- sows after artificial insemination, they will deliver about 114 days of age. After parturition, the piglets are weaned after a 20 to 40-day-old lactation period, and estrus reappears in the sows 4 days after weaning. It is advisable to perform artificial insemination according to the recurrence of the sows in the same manner as described above. By performing artificial insemination in such a cycle, more piglets can be born in the lifetime of one sow.
- the sperm dilution can be easily stored in a freezer. For this reason, it can be melted and used when necessary, and can be easily used in accordance with the timing of the estrous period such as a sow.
- the frozen sperm diluted with the sperm diluent it is preferable to use a frozen sperm obtained by removing seminal plasma from the semen and freezing. Thereby, artificial insemination can be performed in a completely aseptic state, and for example, it can be used for production of a specific disease-free SPF pig.
- artificial insemination may be difficult because seminal plasma has an adverse effect on freezing and cannot be frozen. Even in such a case, artificial insemination can be performed by removing seminal plasma, freezing sperm, and diluting the frozen sperm with the diluent for sperm according to the present embodiment.
- the sperm dilution according to the present embodiment may be used for any artificial insemination of a non-human mammal.
- the sperm diluent according to the present embodiment can be used for non-human mammals such as livestock, but can be particularly suitably used for artificial insemination of multiple fetuses. Since multiple implantation animals such as pigs have a high implantation rate, a large number of fetuses can be born at one time, and the production efficiency can be increased.
- spermatozoa collected only from superior breeding male pigs are used to contribute to the improvement of breeding techniques such as breeding improvement such as meat quality improvement.
- Example 1 Porcine sperm was cultured in a Ca 2+ -containing medium, and the effect of Ca 2+ on phosphorylation of tyrosine residues in sperm proteins was examined.
- mTBM modified Tris-buffer medium
- pig sperm was collected and frozen as follows. Boars used for semen collection were individually raised in individual pig buns and fed with 2.5 kg of seed pig feed twice in the morning and evening. Pigs were vaccinated with Japanese encephalitis / porcine parvovirus infection vaccine. For this study, pigs that were antibody-negative for porcine reproductive and respiratory disorder syndrome (PRRS) and Aujeszky's disease were selected. The semen collection was performed at an interval of one week. Prior to collection, prey was confirmed, signs of illness, etc. were confirmed, the pig was confirmed to be a good pig, and the pig was collected so as not to excite the pig.
- PRRS porcine reproductive and respiratory disorder syndrome
- the suspected female stand was placed in a boar's pig chamber, the male pig was placed on the stand, and the penis and foreskin were washed with physiological saline to remove urine.
- the semen was collected by a manual pressure method, and gauze was put on a previously sterilized cup, and the semen was put into the cup while removing the glue-like substances that are jelly-like substances that come out with the semen.
- For the semen only the first 50 to 100 mL thick portion (there was approximately 80% of the total semen amount) was collected, and the seminal plasma was immediately removed from the semen by centrifugation after collection.
- the sperm is diluted with a pretreatment solution, brought to 15 ° C. over 2.5 hours, and after removal of the supernatant by centrifugation, the solution is maintained in a solution with an osmotic pressure of 400 mOsm / kg for about 1.5 hours, Cooled to 5 ° C.
- the solution used was NSF (Niwa and Sasaki freezing extender; 80% (v / v), 0.31 mol Lactose monohydrate, 20% (v / v) sulfate; an osmotic pressure of 300 mOsm / kg) prepared with ultrapure water to an osmotic pressure of 400 mOsm / kg.
- the porcine frozen sperm obtained as described above was thawed at 60 ° C. for 8 seconds, and the sperm was added to a Ca 2+ -containing medium (mTBM) to culture the sperm. The culture was performed for 3 hours.
- mTBM Ca 2+ -containing medium
- a seminal plasma-containing medium was used, and sperm was added and cultured in the same manner as described above.
- the seminal plasma-containing medium was prepared by adding seminal plasma to the aforementioned Ca 2+ -containing medium (mTBM) so that the final concentration was 10% (v / v).
- the seminal plasma was prepared and used by removing sperm from the collected semen by centrifugation and further removing solids from the supernatant by centrifugation.
- a Ca 2+ -free medium was used, and sperm was added and cultured as described above.
- the Ca 2+ -free medium was prepared by removing the Ca component (CaCl 2 .2H 2 O) from the above-described Ca 2+ -containing medium (mTBM).
- Detection of phosphorylation of tyrosine residues by Western blotting is as follows. 17 ⁇ l of SDS sample buffer was added to sperm stored at ⁇ 80 ° C. and pipetted. Centrifugation was performed at 10,000 rpm for 2 minutes, sonication was performed for 2 minutes, then, heating was performed at 100 ° C. for 5 minutes, and electrophoresis was performed at 100 V for about 2 hours. Transfer to membrane, block with TBS with 5% BSA, and then add 1: 2, to TBS (20 mM Tris-HCl, pH 7.5, 0.15 M NaCl) with 0.5% BSA and 0.1% Tween20 added.
- FIG. 1 shows the detection results of phosphorylation of sperm protein tyrosine residues in each cultured sperm.
- EDTA 0 mM medium and EDTA 3 mM medium EDTA-2Na was removed from the modena solution, and EDTA concentrations were adjusted to 0 mM and 3 mM, respectively.
- the EDTA 6.3 mM medium used the Modena solution as it was.
- the EDTA 12 mM medium was prepared by adding EDTA-2Na to the Modena solution to a concentration of 12 mM.
- Frozen sperm was thawed and added to each medium in the same manner as in Experimental Example 1, and the sperm was cultured.
- the culture time was 1 hour, 3 hours, and 6 hours.
- the sperm motility rate was calculated using a motility analyzer (computer-assisted perm analysis (CASA) system). 5 ⁇ l of the cultured medium was placed on a plate warmed to 38 ° C., and the proportion of sperm moving with a computer was analyzed.
- a motility analyzer computer-assisted perm analysis (CASA) system
- FIG. 2 shows the sperm motility of each cultured cell.
- sperm cultured in EDTA 6.3 mM medium had the highest sperm motility rate.
- sperm was cultured in a medium in which EGTA was further added to EDTA 6.3 mM medium (modena solution) having the highest sperm motility, and measurement of sperm motility after culturing was performed. Phosphorylation detection and sperm acrosome damage rate were measured.
- EGTA 0 mM medium, EGTA 3 mM medium, EGTA 6 mM medium, and EGTA 9 mM medium were prepared. The modena solution was used as it was for the EGTA 0 mM medium. Further, EGTA 3 mM medium, EGTA 6 mM medium, and EGTA 9 mM medium were used by adding EGTA to the Modena solution and adjusting the EGTA concentration in the medium to 3 mM, 6 mM, and 9 mM, respectively. In addition, since pH in the culture medium became acidic when EGTA was added, NaOH was added to adjust the pH to 7.0 to 7.1.
- sperm motility was measured, sperm protein tyrosine phosphorylation was detected, and sperm acrosome damage rate was measured.
- sperm motility and detection of phosphorylation of sperm protein tyrosine residues were performed in the same manner as described above. Moreover, the measurement of the sperm acrosome damage rate was performed as follows. 5 ⁇ l of the medium was smeared on the slide glass, air-dried, and fixed with 99% methanol for 10 minutes. After the methanol was dried, it was marked with a liquid pen. FITC-peanect lectin was added to the smear sperm (approximately 30 ⁇ l per sample) and incubated at 37 ° C. for 30 minutes. Thereafter, the plate was washed with PBS (5 minutes ⁇ 3 times), sealed with DAPI (VECTOR, VECTASHIELD with DAPI, H-1200), and observed after sealing with a manicure.
- PBS 5 minutes ⁇ 3 times
- DAPI VECTOR, VECTASHIELD with DAPI, H-1200
- Fig. 3 shows the measurement results of the sperm motility rate
- Fig. 4 shows the detection results of phosphorylation of sperm protein tyrosine residues after 3 hours of culture
- Fig. 5 shows the measurement results of the sperm acrosome damage rate.
- the sperm motility rate is higher and the sperm acrosome damage rate is lower than when EGTA is not contained.
- sperm cultured in EGTA 6 mM medium has the highest sperm motility, and phosphorylation of tyrosine residues is most suppressed. And it turns out that the sperm acrosome damage rate is also low. From this result, it can be seen that the effect of the sperm dilution increases when EGTA is contained in addition to EDTA, and that the effect is greater when about 6 mM of EGTA is contained.
- the frozen porcine sperm was thawed and added to the EDTA-containing medium and the EDTA / EGTA-containing medium.
- Modena solution was used as the EDTA-containing medium.
- the medium containing EDTA / EGTA was prepared by adding EGTA to the Modena solution to adjust the EGTA concentration to 6 mM.
- FLUO3 is a substance that combines with calcium ions to emit fluorescence. When calcium ions present in the medium are taken up into the sperm cells, FLUO3 and calcium ions are combined in the cells, and fluorescent color is generated in green.
- sperm cultured in an EDTA-containing medium at each culture time emits light more intensely than sperm cultured in an EDTA / EGTA-containing medium.
- sperm cultured in EDTA-containing medium emits very intense light, but in sperm cultured in EDTA / EGTA-containing medium, the middle piece only emits light. . It can be seen that EGTA can suppress calcium ions in the medium from being taken into sperm.
- porcine sperm was cultured in an EDTA-containing medium, an EDTA / EGTA-containing medium, and a seminal plasma-containing medium. For each cultured sperm, phosphorylation detection of tyrosine residues and measurement of sperm motility were performed. Went.
- Modena liquid (EDTA 6.3 mM) was used as it was as the EDTA-containing medium.
- the EDTA / EGTA-containing medium was prepared by adding EGTA to the Modena solution so that the EGTA concentration was 6 mM.
- the seminal plasma-containing medium was prepared by adding seminal plasma to the Modena solution so that the final concentration was 10% (v / v).
- the frozen sperm was thawed and added to each medium, and the sperm was cultured for 1 hour.
- motility was recognized in the sperm cultured in the EDTA / EGTA-containing medium rather than the sperm cultured in the seminal plasma-containing medium.
- a sperm-diluted solution without addition of seminal plasma can be prepared by containing a chelating agent that forms a complex with calcium ions such as EDTA / EGTA in the basic diluent.
- Example 1 Artificial insemination of pigs was performed using artificial semen prepared by adding frozen porcine sperm to a sperm dilution containing EDTA and EGTA.
- EGTA was added to the modena solution to prepare a sperm dilution.
- concentration of EDTA is 6.3 mM
- concentration of EGTA is 6 mM.
- NaOH was added to adjust the pH to 7.0 to 7.1.
- artificial semen A1 Frozen sperm was thawed at 60 ° C. for 8 seconds and immediately added to the sperm diluent to prepare artificial semen (hereinafter referred to as artificial semen A1).
- the concentration of sperm is 1 ⁇ 10 8 sperm / ml.
- the fetus was confirmed on the monitor by ultrasonic pregnancy test.
- the 21st day since pigs estrus in a 21-day cycle, when performing pregnancy test on the 21st day after fertilization, if there is no fertilization or the fertilized egg has regressed, the genital area will be estrus. It is for showing the sign of.
- artificial semen prepared by thawing frozen sperm hereinafter referred to as “serum 10% (v / v)
- serum a seminal plasma-containing diluted solution prepared by adding seminal plasma to Modena solution
- serum a seminal plasma-containing diluted solution prepared by adding seminal plasma to Modena solution
- the conception rate is shown in Table 2, and the implantation rate is shown in Table 3.
- the conception rate was calculated by counting the number of animals with artificial insemination and the number of conception.
- the implantation rate was calculated by counting the total number of luteal bodies and the total number of fetuses in the uterus of 6 sows.
- the artificial semen A1 to which EDTA / EGTA was added had a fertility rate as high as 90% and the same value as the artificial semen B1 to which 10% of seminal plasma was added.
- the implantation rate was 51%, which was lower than 78% of artificial semen B1 to which 10% of seminal plasma was added, and many fetuses were phagocytosed.
- artificial insemination using artificial semen A1 showed a total number of corpora lutea of 51, an intrauterine number of 42, and an in vitro fertilization rate of 82%. Therefore, if the fetus is not phagocytosed, it is thought that it was the same implantation rate as artificial semen B1.
- artificial insemination is performed using artificial semen A1, it is considered that the fetus was phagocytosed due to the breakdown of the intrauterine immune function after fertilization.
- Example 3 From the results of Example 1, it is considered that the presence of seminal plasma is necessary for sperm to perform its original fertilization function and further improve the implantation rate, and sperm phagocytosis can be suppressed in the seminal plasma. It is thought to contain immunosuppressive factors. Thus, an attempt was made to identify immunosuppressive factors in seminal plasma.
- Seminal plasma was collected from 17 boars, and steroid hormones in seminal plasma were measured using the EIA method. Furthermore, cytokines in seminal plasma were detected using a membrane antibody array (Proteome Profiler TM Array, Human Cytokine Array Panel A, ARY005).
- Table 4 shows the results of measurement of steroid hormones in seminal plasma
- FIG. 9 shows the results of detection of cytokines in seminal plasma.
- the seminal plasma contains immunosuppressive factors such as cortisol, MIF, and Serpin E1. If these factors are contained in the diluted solution, it is considered that the improvement of the implantation rate can be realized.
- Example 2 Porcine artificial insemination was performed using artificial semen prepared by adding frozen porcine sperm to a sperm dilution containing cortisol, EDTA, and EGTA.
- cortisol and EGTA were added to the modena solution to prepare a sperm dilution.
- the concentration of cortisol is 100 ng / mL
- the concentration of EDTA is 6.3 mM
- the concentration of EGTA is 6 mM.
- NaOH was added to adjust the pH to 7.0 to 7.1.
- artificial semen A2 The frozen sperm was thawed at 60 ° C. for 8 seconds and immediately added to the sperm diluent to prepare artificial semen (hereinafter referred to as artificial semen A2).
- the concentration of sperm is 1 ⁇ 10 8 sperm / mL.
- the artificial insemination was performed using the sperm dilution solution thus prepared. About the method, it is the same as that of Example 1 except not having administered PMSG to the sow.
- Example 2 artificial insemination was performed in the same manner using artificial semen A1 prepared by diluting frozen sperm with a sperm diluent added with EDTA and EGTA.
- Table 5 shows the conception rate and the implantation rate.
- the conception rate was calculated by counting the number of sows that had undergone artificial insemination and the number of sows that became conceived.
- the implantation rate was calculated by counting the total number of fetuses in the uterus and the total number of corpus luteum of the four sows and averaging them by the number of heads.
- the fertilization rate by artificial insemination using a sperm dilution containing cortisol is 92%, which is improved compared to the absence of cortisol, and the implantation rate is 83%, compared to 51% when no cortisol is added. Has improved significantly.
- the number of leukocytes in the uterus after artificial insemination was measured, as shown in the relative value of the number of leukocytes in utero in FIG. 10, the number of leukocytes in uterus was significantly reduced in artificial semen A2 compared to artificial semen A1. Moreover, it is less than the artificial semen B1 using seminal plasma in Example 1. Therefore, it can be seen that the phagocytosis of the embryo after fertilization was suppressed and the implantation rate was improved by the immunosuppressive action of cortisol.
- corticosteroids steroid hormones such as cortisol
- cortisol corticosteroids
- the mother pigs artificially inseminated using the sperm dilution solution had 4 mothers at the age of 2 months and 6 mothers at the age of 1 month, and there were no abnormal health or miscarriages at all.
- the presence of malformation could not be confirmed, so there was no adverse effect due to the addition of cortisol.
- the sperm dilution contains a chelating agent that forms a complex with calcium ions, and also contains an immunosuppressive factor that suppresses leukocyte migration.
- an immunosuppressive factor that suppresses leukocyte migration.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Dentistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
カルシウムイオンと錯体を形成するキレート剤を含有することを特徴とする。
非ヒト哺乳動物から採精した精液から精漿を除去して凍結した凍結精子を、上記の精子用希釈液で希釈して人工精液を調製し、
前記人工精液を前記非ヒト哺乳動物の子宮内に注入して人工授精を行う、ことを特徴とする。
凍結精子においては、融解後に精子の機能障害が生じることで精子が死滅し、人工授精における受精率が低いこと、そして、精漿が添加された希釈液を用いた場合に、この機能障害が抑制され、高い繁殖成績を示していることを本発明者らは見出した。そして、この機能障害に、カルシウムイオンの存在が精子の運動性とタンパク質のチロシン残基のリン酸化に影響を与えていることを見出し、本実施の形態に係る精子用希釈液を完成させた。
上述した精子用希釈液を用いた人工授精方法について説明する。例示として、以下にブタの人工授精方法について説明する。
Ca2+含有培地でブタの精子を培養し、Ca2+が精子のタンパク質のチロシン残基のリン酸化に及ぼす影響について検討した。
培地にキレート剤を添加してブタの精子を培養することにより、精子の運動性低下、精子先体損傷率、精子タンパク質チロシン残基のリン酸化が抑制されるか否かを検証した。
EDTA及びEGTAを含有する精子用希釈液にブタの凍結精子を添加して調製した人工精液を用い、ブタの人工授精を行った。
実施例1の結果から、精子が本来の受精機能を果たし、着床率を更に向上させるためには、精漿の存在が必要と考えられ、精漿中には、精子の貪食が抑制され得る免疫抑制因子が含まれていると考えられる。そこで、精漿中の免疫抑制因子の同定を試みた。
コルチゾール、EDTA、及びEGTAを含有する精子用希釈液にブタの凍結精子を添加して調製した人工精液を用いて、ブタの人工授精を行った。
Claims (15)
- カルシウムイオンと錯体を形成するキレート剤を含有することを特徴とする精子用希釈液。
- 前記キレート剤がEGTAであることを特徴とする請求項1に記載の精子用希釈液。
- 前記キレート剤がEGTA及びEDTAであることを特徴とする請求項1に記載の精子用希釈液。
- 更に、白血球の遊走を抑制する免疫抑制因子を含有することを特徴とする請求項1乃至3のいずれかに記載の精子用希釈液。
- 前記免疫抑制因子がステロイドホルモン及びサイトカインから選択される一種以上であることを特徴とする請求項4に記載の精子用希釈液。
- 前記ステロイドホルモンがコルチゾール、及び、コルチゾール誘導体から選択される一種以上であることを特徴とする請求項5に記載の精子用希釈液。
- 前記コルチゾール誘導体が、デキサメタゾン、プレドニゾン、及びハイドロコルチゾンから選択される一種以上であることを特徴とする請求項6に記載の精子用希釈液。
- 前記サイトカインがマクロファージ遊走阻止因子、及びSerpin E1から選択される一種以上であることを特徴とする請求項5に記載の精子用希釈液。
- 精漿が除去されて凍結された凍結精子の希釈に用いられることを特徴とする請求項1乃至8のいずれか一項に記載の精子用希釈液。
- 前記凍結精子が非ヒト哺乳動物の凍結精子であることを特徴とする請求項9に記載の精子用希釈液。
- 前記非ヒト哺乳動物が多胎動物であることを特徴とする請求項10に記載の精子用希釈液。
- 前記多胎動物がブタであることを特徴とする請求項11に記載の精子用希釈液。
- 非ヒト哺乳動物から採精した精液から精漿を除去して凍結した凍結精子を、請求項1乃至8のいずれか一項に記載の精子用希釈液で希釈して人工精液を調製し、
前記人工精液を前記非ヒト哺乳動物の子宮内に注入して人工授精を行う、ことを特徴とする人工授精方法。 - 前記非ヒト哺乳動物として多胎動物を用いることを特徴とする請求項13に記載の人工授精方法。
- 前記多胎動物としてブタを用いることを特徴とする請求項14に記載の人工授精方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2765855A CA2765855C (en) | 2009-06-17 | 2010-06-17 | Sperm diluent solution and method for artificial insemination using same |
KR1020127001187A KR101457143B1 (ko) | 2009-06-17 | 2010-06-17 | 정자용 희석액 및 이것을 이용한 인공수정 방법 |
CN201080026618.5A CN102480931B (zh) | 2009-06-17 | 2010-06-17 | 精子用稀释液以及使用其的人工授精方法 |
ES10789568.2T ES2620506T3 (es) | 2009-06-17 | 2010-06-17 | Disolución diluyente de esperma y método para inseminación artificial usando la misma |
EP10789568.2A EP2443920B1 (en) | 2009-06-17 | 2010-06-17 | Sperm diluent solution and method for artificial insemination using same |
US13/378,560 US9439414B2 (en) | 2009-06-17 | 2010-06-17 | Sperm diluent solution and method for artificial insemination using same |
JP2011519844A JP5733829B2 (ja) | 2009-06-17 | 2010-06-17 | 凍結された精子用希釈液、及び、これを用いた人工授精方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009144703 | 2009-06-17 | ||
JP2009-144703 | 2009-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010147194A1 true WO2010147194A1 (ja) | 2010-12-23 |
Family
ID=43356511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/060320 WO2010147194A1 (ja) | 2009-06-17 | 2010-06-17 | 精子用希釈液、及び、これを用いた人工授精方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9439414B2 (ja) |
EP (1) | EP2443920B1 (ja) |
JP (1) | JP5733829B2 (ja) |
KR (1) | KR101457143B1 (ja) |
CN (1) | CN102480931B (ja) |
CA (1) | CA2765855C (ja) |
ES (1) | ES2620506T3 (ja) |
WO (1) | WO2010147194A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117158415A (zh) * | 2023-11-02 | 2023-12-05 | 黑龙江八一农垦大学 | 一种含伊拉米肽的猪精子冷冻保存稀释剂及其应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9383369B2 (en) | 2008-03-31 | 2016-07-05 | Barb Ariel Cohen | Methods for improving fertility and selectivity for desired offspring sex in artificial insemination |
WO2012063687A1 (ja) * | 2010-11-09 | 2012-05-18 | 国立大学法人広島大学 | ヒト凍結精子用希釈液、ヒト凍結精子の希釈方法、及び、ヒトの体外受精用精液又は人工授精用精液の調整方法 |
CN103392670B (zh) * | 2013-08-10 | 2015-06-10 | 内蒙古赛科星繁育生物技术(集团)股份有限公司 | 由种公牛体外受精率对种公牛精子体内受胎率的评价方法 |
WO2015193265A1 (en) | 2014-06-16 | 2015-12-23 | Università degli Studi di Parma | Composition for extenders for the long-term conservation of animal seminal material |
US10603075B1 (en) | 2018-11-30 | 2020-03-31 | Ohana Biosciences, Inc. | Compositions and methods for enhancing sperm function |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000119101A (ja) * | 1998-10-07 | 2000-04-25 | Yamanashi Prefecture | 豚精液保存用希釈液および豚精液の希釈保存法 |
JP2007325313A (ja) | 2000-12-19 | 2007-12-13 | Interdigital Technol Corp | 時分割複信におけるランダムアクセスチャネル用のサブチャネル |
JP2008063235A (ja) * | 2006-09-05 | 2008-03-21 | Natl Fedelation Of Agricult Coop Assoc | 精液希釈液及び希釈精液の保存方法 |
JP2009144703A (ja) | 2007-10-31 | 2009-07-02 | Deere & Co | 無限可変トランスミッション用トルク制限制御を有する作業機械 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3660026B2 (ja) * | 1995-09-04 | 2005-06-15 | 扶桑薬品工業株式会社 | 体外受精用培地組成物 |
US6071231A (en) * | 1997-07-11 | 2000-06-06 | Mendoza; Marco Antonio Hidalgo | Device and method for artificial insemination of bovines and other animals |
FR2793495B1 (fr) * | 1999-05-14 | 2001-08-10 | Imv Technologies | Dilueur pour la cryoconservation de spermatozoides de bovins |
EP1147774A1 (en) * | 2000-04-20 | 2001-10-24 | Stichting Dienst Landbouwkundig Onderzoek | Method for improving the quality of sperm for artificial insemination of animals |
US7138227B2 (en) * | 2001-09-27 | 2006-11-21 | Hirokazu Kusakabe | Frozen spermatozoa compositions and uses thereof |
WO2003065979A2 (en) * | 2001-12-05 | 2003-08-14 | North Shore-Long Island Jewish Research Institute | Methods of diagnosis, monitoring and treatment of fertility |
US20040265831A1 (en) * | 2002-01-08 | 2004-12-30 | Amir Arav | Methods and device for freezing and thawing biological samples |
CN1289661C (zh) | 2004-06-25 | 2006-12-13 | 华中农业大学 | 一种猪精液的保存液 |
US20100003748A1 (en) * | 2008-07-03 | 2010-01-07 | Tony Baker | Compositions, systems, and methods for stabilization of a cell and/or macromolecule |
-
2010
- 2010-06-17 ES ES10789568.2T patent/ES2620506T3/es active Active
- 2010-06-17 KR KR1020127001187A patent/KR101457143B1/ko not_active IP Right Cessation
- 2010-06-17 WO PCT/JP2010/060320 patent/WO2010147194A1/ja active Application Filing
- 2010-06-17 US US13/378,560 patent/US9439414B2/en not_active Expired - Fee Related
- 2010-06-17 CN CN201080026618.5A patent/CN102480931B/zh not_active Expired - Fee Related
- 2010-06-17 JP JP2011519844A patent/JP5733829B2/ja active Active
- 2010-06-17 CA CA2765855A patent/CA2765855C/en not_active Expired - Fee Related
- 2010-06-17 EP EP10789568.2A patent/EP2443920B1/en not_active Not-in-force
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000119101A (ja) * | 1998-10-07 | 2000-04-25 | Yamanashi Prefecture | 豚精液保存用希釈液および豚精液の希釈保存法 |
JP2007325313A (ja) | 2000-12-19 | 2007-12-13 | Interdigital Technol Corp | 時分割複信におけるランダムアクセスチャネル用のサブチャネル |
JP2008063235A (ja) * | 2006-09-05 | 2008-03-21 | Natl Fedelation Of Agricult Coop Assoc | 精液希釈液及び希釈精液の保存方法 |
JP2009144703A (ja) | 2007-10-31 | 2009-07-02 | Deere & Co | 無限可変トランスミッション用トルク制限制御を有する作業機械 |
Non-Patent Citations (6)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117158415A (zh) * | 2023-11-02 | 2023-12-05 | 黑龙江八一农垦大学 | 一种含伊拉米肽的猪精子冷冻保存稀释剂及其应用 |
CN117158415B (zh) * | 2023-11-02 | 2024-02-02 | 黑龙江八一农垦大学 | 一种含伊拉米肽的猪精子冷冻保存稀释剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2620506T3 (es) | 2017-06-28 |
KR20120028388A (ko) | 2012-03-22 |
CA2765855C (en) | 2015-02-03 |
CA2765855A1 (en) | 2010-12-23 |
JP5733829B2 (ja) | 2015-06-10 |
KR101457143B1 (ko) | 2014-11-03 |
CN102480931B (zh) | 2015-01-07 |
US20120197068A1 (en) | 2012-08-02 |
CN102480931A (zh) | 2012-05-30 |
JPWO2010147194A1 (ja) | 2012-12-06 |
EP2443920B1 (en) | 2016-12-21 |
EP2443920A1 (en) | 2012-04-25 |
EP2443920A4 (en) | 2013-08-14 |
US9439414B2 (en) | 2016-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
King et al. | Lambing rates and litter sizes following intrauterine or cervical insemination of frozen/thawed semen with or without oxytocin administration | |
Al-Katanani et al. | Pregnancy rates following timed embryo transfer with fresh or vitrified in vitro produced embryos in lactating dairy cows under heat stress conditions | |
Neglia et al. | Reproductive management in buffalo by artificial insemination | |
Yusuf et al. | Reproductive performance of repeat breeders in dairy herds | |
Nogueira et al. | Timed artificial insemination plus heat I: effect of estrus expression scores on pregnancy of cows subjected to progesterone–estradiol-based protocols | |
Hori et al. | Artificial insemination of frozen epididymal sperm in beagle dogs | |
Garde et al. | The application of reproductive technologies to natural populations of red deer | |
Brown | Comparative reproductive biology of elephants | |
JP5733829B2 (ja) | 凍結された精子用希釈液、及び、これを用いた人工授精方法 | |
Presicce | Reproduction in the water buffalo | |
Lonergan et al. | Role of diestrus progesterone on endometrial function and conceptus development in cattle | |
Jha et al. | Effects of number of frozen-thawed ram sperm and number of inseminations on fertility in synchronized ewes under field condition | |
Kasimanickam et al. | Sire effect on the pregnancy outcome in beef cows synchronized with progesterone based Ovsynch and CO-Synch protocols | |
De Castro et al. | Effect of recombinant gonadotropins on embryo quality in superovulated rabbit does and immune response after repeated treatments | |
D’Alessandro et al. | Superovulatory response to gonadotrophin FSH/LH treatment and effect of progestin supplement to recipients on survival of transferred vitrified embryos in goats | |
Sayid | Fertilization failure and early embryonic mortality as a major cause of reproductive failure in cattle: A review | |
Defensor et al. | Effect of Treatment With Gonadoreline at the Embryo Transfer on Pregnancy Outcomes in Bovine. | |
JP4783883B2 (ja) | 受胎率および産子数向上凍結精子およびその製法 | |
JP5422848B2 (ja) | 受胎率および産子数向上凍結精子およびその製法 | |
Hansen | Compromised Pregnancy Success Caused by Heat Stress | |
Korkmaz et al. | Evaluation of the Ovsynch and Co-synch protocols on estrus intensity and pregnancy rate in Anatolian buffalo heifers | |
Fair et al. | The difference in embryo quality between Belclare and Suffolk ewes is not due to differences in oocyte quality | |
dos Santos et al. | Effect of gonadorelin treatment in embryo transfer on pregnancy outcomes in cattle | |
Zambrano-Varon | Studies in the superovulatory response to gonadotropins and folliculogenesis of water buffalo (Bubalus bubalis) | |
Elsden et al. | Imakawa, D. 663 Ingraham, RH 381 Ireland, JJ 389 Irvine, CH 607 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080026618.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10789568 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2011519844 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2765855 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127001187 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010789568 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010789568 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13378560 Country of ref document: US |